Phase II Single Arm Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma

Trial Profile

Phase II Single Arm Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Isatuximab (Primary) ; Diphenhydramine; Methylprednisolone; Ranitidine
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2017 Planned number of patients changed from 63 to 61.
    • 08 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 12 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top